Group Says FDA Should Have Emphasized Auditing More Than Testing for Melamine
This article was originally published in The Gold Sheet
Executive Summary
FDA criticized for stressing testing rather than auditing in melamine guidance
You may also be interested in...
FDA Identifies Excipients At Risk for Potential Melamine Contamination
Which excipients might be vulnerable to melamine substitution? FDA provides its list of 23 at-risk excipients and recommends specific steps for safeguarding them.
FDA Offers More Flexibility on Residual Solvents in Generic Drug Applications
More flexibility on residual solvents obtained from FDA's Office of Generic Drugs.
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.